Published in Health and Medicine Week, November 22nd, 2004
Lipid Sciences' patented HDL therapy technology, designed for the treatment of cardiovascular disease, has now entered a safety and efficacy study, with significant support from RxGen's preclinical research capabilities.
RxGen's preclinical research capabilities allow business partners to test and validate experimental therapeutic products in human primate models of human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.